Roche buys Poseida Therapeutics for $1.5 billion | EUROtoday

Listen to the audio model of the article

Roche has entered into an settlement to purchase US biopharmaceutical firm Poseida Therapeutics, a pioneer in donor-derived CAR-T cell therapies, for a consideration that might attain $1.5 billion. Roche will supply $9 per share in money at closing, for a complete of $1 billion, plus a non-negotiable contingent worth proper (CVR) as much as a complete of $4 per share. The value payable at closing represents a premium of roughly 215% over the closing value of Poseida shares on November 25. The settlement was authorized unanimously by the boards of administrators of Roche and Poseida. The acquisition builds on the partnership between Roche and Poseida following the 2022 collaboration settlement, which focuses on the event of ready-to-use CAR-T cell therapies to deal with the medical wants of sufferers with hematological malignancies. The transaction is anticipated to shut within the first quarter of 2025.